Date: 2016-01-12
Type of information: Private placement
Company: Cempra (USA - NC)
Investors:
Amount: $93.7 million
Funding type: private placement
Planned used: Cempra intends to use the net proceeds from the offering to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S. , subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta® in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.
Others: * On January 12, 2016, Cempra announced that it has completed its previously announced underwritten public offering of 4,166,667 shares of its common stock at a price of $24.00 per share. Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $93.7 million . The company also has granted the underwriters a 30-day option to purchase up to an additional 625,000 shares, which would result in additional net proceeds of approximately $14.1 million , if exercised in full. * On January 6, 2016, Cempra announced that it has priced an underwritten public offering of 4,166,667 shares of its common stock at a price of $24.00 per share for aggregate gross proceeds of approximately $100 million . Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $93.7 million . The company also has granted the underwriters a 30-day option to purchase up to an additional 625,000 shares, which would result in additional net proceeds of approximately $14.1 million , if exercised in full. * On January 5, 2016, Cempra announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $175 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering with an aggregate public offering price of $26.25 million. J.P. Morgan Securities LLC is acting as lead active book-running manager and Jefferies LLC is acting as joint active book-running manager for the offering.
Therapeutic area: Infectious diseases
